Severe limb ischemia represents a critical condition, being associated with high morbidity and mortality rates. Patients with critical limb ischemia (CLI) require urgent initiation of interventional or surgical treatment, as restoration of the blood flow is the only way to ensure limb salvage in these critical cases. At the same time, in acute limb ischemia, a dramatic form of sudden arterial occlusion of the lower limbs, the integrity of the limb is also seriously threatened in the absence of urgent revascularization. From patients with CLI, 40% are "no option CLI", meaning patients in whom, due to anatomical considerations or to the severity of the lesions, there is no possibility to perform interventional or surgical treatment or they have failed. Therapeutic angiogenesis has been proposed to serve as an effective and promising alternative therapy for patients with severe limb ischemia who do not have any other option for revascularization. This review aims to present the current status in therapeutic angiogenesis and the role of different approaches (gene or cell therapy, intra-arterial vs. intramuscular injections, different sources of cells) in increasing the rates of limb salvage in patients with severe ischemia of the lower limbs.
INTRODuCTION
Severe limb ischemia represents a critical condition, being associated with high morbidity and mortality rates.
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Critical limb ischemia (CLI) is usually caused by one or multiple occlusions in the peripheral arteries of the lower limbs and results from the progressive evolution of a chronic peripheral arterial disease to a stage in which the viability of the affected limb is seriously threatened. [5] [6] [7] In this case, the condition becomes a vascular emergency, as prompt initiation of adequate therapeutic measures restoring the blood flow is the only way to ensure limb salvage. [8] [9] [10] At the same time, severe ischemia can represent the clinical manifestation of acute limb ischemia, a dramatic form of sudden arterial occlusion of the lower limbs, in which the integrity of the limb is seriously threatened in the absence of urgent revascularization.
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Acute limb ischemia, defined as ischemia of the lower extremities lasting no longer than 14 days, has a reported 1-year mortality rate of over 40% and is 20 times more common in the lower limbs than in the upper extremities. 13 Unfortunately, 50% of CLI patients do not present any symptoms 6 months prior to the onset of CLI, which makes it difficult to establish an effective preventive strategy.
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The prognosis associated with CLI is extremely severe in the absence of flow restoration, with a 1-year mortality of 20% and a 1-year amputation rate of 40%. 14, 16, 17 From patients with CLI, 25% progress each year to limb amputation, while 40% of patients are "no option CLI". 14, 18 The class of "no option CLI patients" represents a group of patients in whom, due to anatomical considerations or to the severity of the lesions, there is no possibility to perform interventional or surgical treatment or they have failed. Despite the recent progresses encountered in interventional devices, in a significant number of cases interventional therapy still fails to reopen the occluded peripheral arteries.
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Therapeutic angiogenesis via cellular transplantation has been proposed to serve as an effective and promising alternative therapy for the treatment of patients with severe limb ischemia who have no other option for revascularization. Two methods have been proposed for achieving therapeutic angiogenesis: gene therapy and cell therapy ( Figure   1 ). 46, 47 Each of them has encouraging preclinical results;
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THERAPEuTIC ANgIOgENESIS -A NEw CONCEPT IN vASCuLAR CARE
however, while cell therapy seems to represent a promising approach, being associated with a moderate clinical improvement, gene therapy failed to convincingly demonstrate a substantial benefit in terms of clinical endpoints. 
Therapeutic angiogenesis
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The main results of the clinical studies in SC therapy for CLI, using intramuscular and intra-arterial routes, are presented in Table 1 . The main disadvantage of these studies is the limited sample size, which makes it difficult to reach statistical significance or to generalize the conclusions.
In intramuscular applications, the injection of autolo- 
AlTered reSponSe To Sc TherApy
In a study by Idei et In a pre-clinical study in pigs, absolute myocardial healthy subjects and showed that both cell populations have a similar ability to restore altered perfusion in murine ischemic hind limbs.
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The ATheroproTecTive effecT of Scs
A serious concern related to SC therapy in cardiovascular applications has been raised by several authors who claimed that angiogenic factors could destabilize atherosclerotic plaques as a result of their angiogenic effects on vasa vasorum. 48 However, no clinical experience confirmed this hypothesis. 
clinicAl TriAlS for Sc TherApy in cli
TACT was the first published trial demonstrating the potential role of BM-MNCs in the treatment of CLI. In this trial, SC administration using the intramuscular route was associated with a 60% amputation-free rate at 3 years, a significant improvement in the leg pain scale, a significant reduction in ulcer size, and a significant increase in painfree walking distance. 86 PROVASA was a clinical trial assessing the role of intraarterial injection of SCs for the treatment of CLI. 87 The study enrolled 40 patients randomized to BM therapy vs.
placebo. There was no significant difference in the eventfree survival rates; however, a non-significant improve- 
